Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist

BACKGROUND: Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate Cancer Prostatic Dis
Autors principals: Margel, David, Ber, Yaara, Peer, Avivit, Shavit-Grievink, Liat, Pinthus, Jehonathan H., Witberg, Guy, Baniel, Jack, Kedar, Daniel, Rosenbaum, Eli
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8012206/
https://ncbi.nlm.nih.gov/pubmed/32737420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0264-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars